Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Chronic myeloid leukemia stem cells.

Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, Saglio G, Gale RP.

Leukemia. 2019 Jul;33(7):1543-1556. doi: 10.1038/s41375-019-0490-0. Epub 2019 May 24. Review.

PMID:
31127148
2.

An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy.

D'Apice L, Cuccaro F, Varriale S, Cipria D, Sartorius R, Circosta P, Cignetti A, Salerno M, Coscia MR, Oreste U, Marzullo VM, Martini G, Acuto O, De Berardinis P.

J Immunother. 2019 May;42(4):97-109. doi: 10.1097/CJI.0000000000000259.

PMID:
30865026
3.

Correction to Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.

Sainas S, Pippione AC, Lupino E, Giorgis M, Circosta P, Gaidano V, Goyal P, Bonanni D, Rolando B, Cignetti A, Ducime A, Andersson M, Järvå M, Friemann R, Piccinini M, Ramondetti C, Buccinnà B, Al-Karadaghi S, Boschi D, Saglio G, Lolli ML.

J Med Chem. 2019 Feb 14;62(3):1696. doi: 10.1021/acs.jmedchem.9b00057. Epub 2019 Jan 29. No abstract available.

PMID:
30694669
4.

Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect.

Circosta P, Vitaggio K, Elia AR, Todorovic M, Sangiolo D, Carnevale-Schianca F, Vallario A, Geuna M, Aglietta M, Cignetti A.

Immunotherapy. 2018 Jul;10(9):753-767. doi: 10.2217/imt-2017-0139.

PMID:
30008257
5.

Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.

Sainas S, Pippione AC, Lupino E, Giorgis M, Circosta P, Gaidano V, Goyal P, Bonanni D, Rolando B, Cignetti A, Ducime A, Andersson M, Järvå M, Friemann R, Piccinini M, Ramondetti C, Buccinnà B, Al-Karadaghi S, Boschi D, Saglio G, Lolli ML.

J Med Chem. 2018 Jul 26;61(14):6034-6055. doi: 10.1021/acs.jmedchem.8b00373. Epub 2018 Jul 9. Erratum in: J Med Chem. 2019 Feb 14;62(3):1696.

PMID:
29939742
6.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.

7.

Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients.

Bruno B, Busca A, Vallero S, Raviolo S, Mordini N, Nassi L, Cignetti A, Audisio E, Festuccia M, Corsetti A, Depaoli L, Faraci M, Micalizzi C, Corcione S, Berger M, Saglio F, Caropreso P, Mengozzi G, Squadrone V, De Rosa FG, Giaccone L.

Expert Rev Hematol. 2017 Jun;10(6):543-550. doi: 10.1080/17474086.2017.1326813. Epub 2017 May 24. Review.

PMID:
28471695
8.

Cytokine-induced killer cells engineered with exogenous T-cell receptors directed against melanoma antigens: enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition.

Elia AR, Circosta P, Sangiolo D, Bonini C, Gammaitoni L, Mastaglio S, Genovese P, Geuna M, Avolio F, Inghirami G, Tarella C, Cignetti A.

Hum Gene Ther. 2015 Apr;26(4):220-31. doi: 10.1089/hum.2014.112. Epub 2015 Apr 13.

PMID:
25758764
9.

The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations.

Bodini M, Ronchini C, Giacò L, Russo A, Melloni GE, Luzi L, Sardella D, Volorio S, Hasan SK, Ottone T, Lavorgna S, Lo-Coco F, Candoni A, Fanin R, Toffoletti E, Iacobucci I, Martinelli G, Cignetti A, Tarella C, Bernard L, Pelicci PG, Riva L.

Blood. 2015 Jan 22;125(4):600-5. doi: 10.1182/blood-2014-05-576157. Epub 2014 Dec 12. Review.

10.

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, Pelicci PG.

Blood Cancer J. 2014 Mar 21;4:e195. doi: 10.1038/bcj.2014.19. No abstract available.

11.

The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA).

Boita M, Guida G, Circosta P, Elia AR, Stella S, Heffler E, Badiu I, Martorana D, Mariani S, Rolla G, Cignetti A.

Clin Immunol. 2014 May-Jun;152(1-2):152-63. doi: 10.1016/j.clim.2014.03.001. Epub 2014 Mar 13.

PMID:
24632064
12.

Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.

Riva L, Ronchini C, Bodini M, Lo-Coco F, Lavorgna S, Ottone T, Martinelli G, Iacobucci I, Tarella C, Cignetti A, Volorio S, Bernard L, Russo A, Melloni GE, Luzi L, Alcalay M, Dellino GI, Pelicci PG.

Blood Cancer J. 2013 Sep 13;3:e147. doi: 10.1038/bcj.2013.46. No abstract available.

13.

Haploidentical cellular therapy in elderly patients with acute myeloid leukemia: description of its use in high risk patients.

Cignetti A, Ruella M, Elia A, Tassi V, Redoglia V, Gottardi D, Tarella C.

Am J Hematol. 2013 Aug;88(8):720-1. doi: 10.1002/ajh.23483. Epub 2013 Jun 28. No abstract available.

14.

Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene.

Casucci M, Perna SK, Falcone L, Camisa B, Magnani Z, Bernardi M, Crotta A, Tresoldi C, Fleischhauer K, Ponzoni M, Gregori S, Caligaris Cappio F, Ciceri F, Bordignon C, Cignetti A, Bondanza A, Bonini C.

Mol Ther. 2013 Feb;21(2):466-75. doi: 10.1038/mt.2012.227. Epub 2012 Nov 13.

15.

Lymphocyte transformation and autoimmune disorders.

Tarella C, Gueli A, Ruella M, Cignetti A.

Autoimmun Rev. 2013 Jun;12(8):802-13. doi: 10.1016/j.autrev.2012.11.004. Epub 2012 Dec 4. Review.

PMID:
23219771
16.

Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers.

Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D.

J Immunother. 2012 Sep;35(7):579-86.

PMID:
22892454
17.

Expression of NKG2D and CD107 in CD8(+) effector memory lymphocytes in Churg-Strauss syndrome.

Boita M, Rolla G, Mallone R, Martinuzzi E, Heffler E, Circosta P, Elia AR, Cignetti A, Caillat-Zucman S, de Menthon M, Guida G.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S57-61. Epub 2012 May 14.

PMID:
22640649
18.

High basal γH2AX levels sustain self-renewal of mouse embryonic and induced pluripotent stem cells.

Turinetto V, Orlando L, Sanchez-Ripoll Y, Kumpfmueller B, Storm MP, Porcedda P, Minieri V, Saviozzi S, Accomasso L, Cibrario Rocchietti E, Moorwood K, Circosta P, Cignetti A, Welham MJ, Giachino C.

Stem Cells. 2012 Jul;30(7):1414-23. doi: 10.1002/stem.1133.

19.

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors.

Leuci V, Mesiano G, Gammaitoni L, Cammarata C, Capellero S, Todorovic M, Jordaney N, Circosta P, Elia A, Lesnikova M, Georges GE, Piacibello W, Fagioli F, Cignetti A, Aglietta M, Sangiolo D.

J Biotechnol. 2011 Dec 10;156(3):218-26. doi: 10.1016/j.jbiotec.2011.09.001. Epub 2011 Sep 10.

PMID:
21933686
20.

TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells.

Orlando L, Accomasso L, Circosta P, Turinetto V, Lantelme E, Porcedda P, Minieri V, Pautasso M, Willemsen RA, Cignetti A, Giachino C.

Mol Immunol. 2011 Jul;48(12-13):1369-76. doi: 10.1016/j.molimm.2011.02.015. Epub 2011 Apr 8.

PMID:
21481940
21.

T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.

Circosta P, Granziero L, Follenzi A, Vigna E, Stella S, Vallario A, Elia AR, Gammaitoni L, Vitaggio K, Orso F, Geuna M, Sangiolo D, Todorovic M, Giachino C, Cignetti A.

Hum Gene Ther. 2009 Dec;20(12):1576-88. doi: 10.1089/hum.2009.117.

PMID:
19678763
22.

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.

Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A.

Expert Opin Biol Ther. 2009 Jul;9(7):831-40. doi: 10.1517/14712590903005552. Review.

PMID:
19463075
23.

Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages.

Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S.

J Exp Med. 2008 Jul 7;205(7):1673-85. doi: 10.1084/jem.20072602. Epub 2008 Jun 16.

24.

Clonal CD8+ TCR-Vbeta expanded populations with effector memory phenotype in Churg Strauss syndrome.

Guida G, Vallario A, Stella S, Boita M, Circosta P, Mariani S, Prato G, Heffler E, Bergia R, Sottile A, Rolla G, Cignetti A.

Clin Immunol. 2008 Jul;128(1):94-102. doi: 10.1016/j.clim.2008.03.505. Epub 2008 May 23.

PMID:
18502180
25.

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers.

Sangiolo D, Martinuzzi E, Todorovic M, Vitaggio K, Vallario A, Jordaney N, Carnevale-Schianca F, Capaldi A, Geuna M, Casorzo L, Nash RA, Aglietta M, Cignetti A.

Int Immunol. 2008 Jul;20(7):841-8. doi: 10.1093/intimm/dxn042. Epub 2008 May 9.

PMID:
18469328
26.

The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment.

Rolny C, Capparuccia L, Casazza A, Mazzone M, Vallario A, Cignetti A, Medico E, Carmeliet P, Comoglio PM, Tamagnone L.

J Exp Med. 2008 May 12;205(5):1155-71. doi: 10.1084/jem.20072509. Epub 2008 May 5.

27.

Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.

Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G.

Cancer Res. 2007 Jun 1;67(11):5300-7.

28.

Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD.

Carnevale-Schianca F, Cignetti A, Capaldi A, Vitaggio K, Vallario A, Ricchiardi A, Sperti E, Ferraris R, Gatti M, Grignani G, Rota-Scalabrini D, Geuna M, Fizzotti M, Sangiolo D, Sottile A, De Rosa G, Bucci AR, Lambertenghi-Deliliers G, Benedetti E, Nash R, Aglietta M.

Blood. 2006 May 1;107(9):3795-803. Epub 2006 Jan 10.

29.

Degradation of pyrimethanil in soil: influence of light, oxygen, and microbial activity.

Vanni A, Anfossi L, Cignetti A, Baglieri A, Gennari M.

J Environ Sci Health B. 2006;41(1):67-80.

PMID:
16393896
30.

Lentiviral transduction of primary myeloma cells with CD80 and CD154 generates antimyeloma effector T cells.

Cignetti A, Vallario A, Follenzi A, Circosta P, Capaldi A, Gottardi D, Naldini L, Caligaris-Cappio F.

Hum Gene Ther. 2005 Apr;16(4):445-56.

PMID:
15871676
31.

Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses.

Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L, Ghia P, Caligaris-Cappio F.

J Immunol. 2004 Aug 15;173(4):2855-65.

32.

The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation.

Cignetti A, Vallario A, Roato I, Circosta P, Strola G, Scielzo C, Allione B, Garetto L, Caligaris-Cappio F, Ghia P.

Exp Hematol. 2003 Jun;31(6):495-503.

PMID:
12829025
33.

Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas.

Caligaris-Cappio F, Cignetti A, Granziero L, Ghia P.

Best Pract Res Clin Haematol. 2002 Sep;15(3):563-75. Review.

PMID:
12468406
34.

Influence of soil organic matter on the leaching of polycyclic aromatic hydrocarbons in soil.

Petruzzelli L, Celi L, Cignetti A, Marsan FA.

J Environ Sci Health B. 2002 May;37(3):187-99.

PMID:
12009190
35.

Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression.

Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R.

Hematol J. 2000;1(1):7-14.

PMID:
11920164
36.

Liquid chromatographic determination of triasulfuron in soil.

Gennari M, Ferraris L, Nègre M, Cignetti A.

J AOAC Int. 2000 Sep-Oct;83(5):1076-81.

PMID:
11048847
38.

CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.

Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA.

Blood. 1999 Sep 15;94(6):2048-55.

39.

IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia.

de Totero D, Reato G, Mauro F, Cignetti A, Ferrini S, Guarini A, Gobbi M, Grossi CE, Foa R.

Br J Haematol. 1999 Mar;104(3):589-99.

PMID:
10086799
40.

Platelet-activating factor synthesized by IL-12-stimulated polymorphonuclear neutrophils and NK cells mediates chemotaxis.

Bussolati B, Mariano F, Cignetti A, Guarini A, Cambi V, Foà R, Piccoli G, Camussi G.

J Immunol. 1998 Aug 1;161(3):1493-500.

41.

Microsatellite analysis in childhood acute lymphoblastic leukemia.

Reato G, Basso G, Putti MC, Cignetti A, Guarini A, Foa R.

Haematologica. 1998 May;83(5):403-7.

42.

Control of the membrane sex hormone-binding globulin-receptor (SHBG-R) in MCF-7 cells: effect of locally produced SHBG.

Fortunati N, Raineri M, Cignetti A, Hammond GL, Frairia R.

Steroids. 1998 May-Jun;63(5-6):282-4.

PMID:
9618786
43.

Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts.

Vitale A, Guarini A, Latagliata R, Cignetti A, Foa R.

Br J Haematol. 1998 Apr;101(1):150-7.

PMID:
9576195
45.

Human lung carcinoma cells engineered to release IL2, IL7, GM-CSF and TNF alpha.

Guarini A, Riera L, Reato G, Carbone A, Cignetti A, Tos A, Lanfrancone L, Melani C, Paul R, Forni G, Foa R.

Int J Oncol. 1996 Apr;8(4):765-72.

PMID:
21544424
47.

The IL-2 receptor complex: expression and function on normal and leukemic B cells.

de Totero D, Francia di Celle P, Cignetti A, Foa R.

Leukemia. 1995 Sep;9(9):1425-31. Review.

PMID:
7658707
48.

Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression.

Cignetti A, Guarini A, Carbone A, Forni M, Cronin K, Forni G, Gansbacher B, Foa R.

J Natl Cancer Inst. 1994 May 18;86(10):785-91.

PMID:
8169977
49.

Cytokine gene therapy: a new strategy for the management of cancer patients.

Foa R, Guarini A, Cignetti A, Cronin K, Rosenthal F, Gansbacher B.

Nat Immun. 1994 Mar-Jun;13(2-3):65-75. Review.

PMID:
8173237
50.

Cytokine gene therapy in oncology.

Foa R, Cignetti A, Riera L, Gillio Tos A, Guarini A.

Folia Biol (Praha). 1994;40(1-2):37-48. Review.

PMID:
7958063

Supplemental Content

Loading ...
Support Center